Ventilator Associated Pneumonia (VAP) Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens
The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or healthcare-associated bacterial pneumonia (HCABP) caused by Gram-negative pathogens.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
| Completed |
NCT01782755 -
Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial
|
Phase 2 | |
| Completed |
NCT02440828 -
Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia
|
Phase 4 | |
| Terminated |
NCT02652247 -
Serial, Non-invasive Analysis of Exhaled Breath Condensate in Ventilated Trauma Patients
|
N/A | |
| Active, not recruiting |
NCT05792501 -
Pulmonary Infections and Barotrauma Associated With MV IN PICU
|